Immunovia’s Presentation of Q2 2022 Report, on August 24, 2022
Immunovia AB published the company’s Interim Report January-June 2022 on Wednesday, August 24, 2022, at 8:30 am CET.
Place: Immunovia website
Immunovia, Philipp Mathieu, CEO and President, presented at Gilmartin Group Emerging Growth Conference on August 31, 2022
IMMray™ PanCan-d is provided as a laboratory developed test (LDT) exclusively by Immunovia, Inc. in the US.
The Immunovia AB share is, since 3 April 2018, traded on Nasdaq Stockholm. Immunovia has one class of shares. The Company has a registered share capital of SEK 1,131,579.05 allocated among 22,631,581 shares. The par value of the shares is SEK 0.05 per share.
Ticker on Nasdaq Stockholm: IMMNOV
The shares are registered by Euroclear Sweden.
If you have further questions, please contact our IR contact.
If you are interested in receiving our press releases and reports, please click on “Subscribe”.